cited in the European Search Report of EP 4 # 1 988 XP-002550126 Your Ref.: 637 (164 4)

WPI / Thomson

- 1992-253494 [31] AN
- AP - JP19900293763 19901101
- R03875-M R00179-M R01833-M R00206-M R04255-M R04470-M R04471-M

CPY - NISS-N

DC - B05 D13

DCR - [1] 114178 CMP; 4015 CMP USE; 51640 CMP; 7434 CMP USE; 95874 CMP; 97621 CMP

DR - 0179-U 0206-U 1833-U

- 199231

IN - IKEGAWA N; IKEGAWA T; ITAKURA H; MIZUNUMA H; NAKAJIMA O; YAMAGAMI S

LNKA- 1992-112790

- [03] M423 M431 M782 M903 P446 P522 P714 P814 Q220 Q271 V400 V406 V600 V645 V780

- [01] H7 H723 M226 M232 M320 M416 M431 M610 M782 M903 M904 P446 P522 м2 P714 P814 Q220; R03875-M
 - [02] D012 D016 D025 D120 H4 H401 H441 H8 M210 M211 M225 M232 M240 M283 M320 M412 M431 M511 M520 M530 M540 M782 M903 M904 M910 P446 P522 P714 P814 Q220 V0 V350; R00179-M
 - [04] B415 B701 B713 B720 B815 B831 H1 H181 H721 H722 J0 J012 J2 J272 K0 L7 L722 M210 M211 M225 M231 M262 M273 M282 M283 M312 M313 M321 M332 M342 M343 M383 M392 M411 M431 M510 M520 M530 M540 M620 M782 M903 M904 M910 P446 P522 P714 P814 Q220 V0 V771; R01833-M
 - [05] H7 H721 H722 H723 J0 J011 J1 J171 M225 M226 M231 M262 M281 M320 M416 M431 M782 M903 M904 P446 P522 P714 P814 Q220; R00206-M R04255-M R04470-M R04471-M
- MC - B03-H B04-B01B B04-B01C1 B04-B01C2 B05-B01P B10-C04E B10-J02 B12-C10 B12-F01B B12-H03 B12-J01 D03-H01T
- (NISS-N) NISSEI MARINE KOGYO KK PA
- PN - JP4169525 A 19920617 DW199231
- PR - JP19900293763 19901101
- XIC A23L-001/30; A61K-031/01; A61K-031/185; A61K-031/20; A61K-031/201; A61K-031/202; A61K-031/21; A61K-031/23; A61K-031/352; A61K-031/355; A61R-031/66; A61R-031/683; A61R-031/685; A61P-003/00; A61P-003/06
- AB - Pharmaceutical compsn. for improving serum lipid contains squalene, fish oil and vitamin E. This compsn. contains squalene (30-85 wt.%), fish oil (5-50 wt.%), soybean lecithin (5-50 wt.%), vegetable oil (5-50 wt.%) and vitamin E (0.1-10 wt.%). Fish oil contains at least 20 wt.% of eicosapentaenoic acid and at least 10 wt.% of docosahexaenoic acid. Vegetable oil contains at least 50 wt.% of linolic acid and at least 7 wt.% of gamma-linolenic acid.
 - USE/ADVANTAGE :

This compsn. can be used as a food material or a food additive. This is effective for hyperlipemia and gives a quick response without side effects (LD50 in mice at least 35g/kg orally). This is applicable to the treatment of prophylaxis of cerebral infarction and myocardial infarction.

In an example, the compsn. contained squalene (55.56 wt.%), fish oil (16.67 wt.%), soybean lecithin (12.22 wt.%), evening primrose oil (13.33 wt.%) and vitamin E oil (2.22 wt.%). The compsn. (900mg) was adminstered to a hyperlipemic patient 3 times a day for 4 months. One

Page 1

15.10.2009 08:34:03

- month after the admin., all kinds of lipids in blood were settled in their normal values
- ICAI- A23L1/30; A61K31/01; A61K31/20; A61K31/201; A61K31/202; A61K31/23; A61K31/355; A61K31/66; A61K31/685; A61P3/06
- ICCI- A23L1/30; A61K31/01; A61K31/185; A61K31/21; A61K31/352; A61K31/66; A61K31/683; A61P3/00
- INW IKEGAWA N; IKEGAWA T; ITAKURA H; MIZUNUMA H; NAKAJIMA O; YAMAGAMI S
- IW COMPOSITION CONTAIN SQUALENE FISH OIL VITAMIN=E TREAT HYPERLIPAEMIA PREVENT CEREBRAL MYOCARDIUM INFARCTION
- IWW COMPOSITION CONTAIN SQUALENE FISH OIL VITAMIN=E TREAT HYPERLIPAEMIA PREVENT CEREBRAL MYOCARDIUM INFARCTION
- NC 1
- NPN 1
- OPD 1990-11-01
- PAW (NISS-N) NISSEI MARINE KOGYO KK
- PD 1992-06-17
- TI Compsn. contg. squalene, fish oil and vitamin=E for treating hyperlipidaemia, also for treating and preventing cerebral and myocardial infarction

15.10.2009 08:34:03